This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Preliminary Report, with Special Reference to the Successful Response of Patients Resistant to Other Antimalarial Drugs

ROBERTS B. PAPPENFORT, M.D.; Capt. JAMES H. LOCKWOOD

AMA Arch Derm. 1956;74(4):384-386.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Amodiaquin (Camoquin), first synthesized in 1946 by Burckhalter and associates,¹ is one of the 4-aminoquinolines, a group of compounds discovered after the development of quinacrine (Atabrine). Extensive investigations in the period 1946 to 1954 with these compounds, particularly chloraquine and amodiaquin, firmly established their value in the suppressive treatment of vivax and falciparum malaria.² The value of chloroquine and quinacrine in the treatment of discoid lupus erythematosus is well established and need not be reviewed.

Having almost simultaneously encountered two patients with chronic discoid lupus erythematosus who failed to respond to quinacrine and chloroquine therapy, we decided to try amodiaquin, since a small supply was available to one of us (R. B. P.) through a local pharmacy. The results in these and in subsequent patients were very gratifying, thus prompting this preliminary report.

Report of Cases

CASE 1.—A 31-year-old white woman was . . . [Full Text PDF of this Article]

Author Affiliations
San Diego, Calif.; (MC), U.S.N.

From the private practice of Dr. R. B. pappenfort, and the Dermatology Service of Capt. James H. Lockwood (MC), U.S.N., U. S. Naval Hospital, San Diego, Calif.

Footnotes
Submitted for publication Nov. 28, 1955.

Camoquin hydrochloride is supplied by Parke-Davis & Company, in tablets of 0.20 gm. of Camoquin base.

Permission was given by Philip K. Allen, M.D., for the use of Cases 3, 4, and 8; by Werner W. Duemling, M.D., for Case 5, and by Leonard C. Greenfield, M.D., for Cases 6 and 7.

The opinions or assertions contained herein are the private ones of the writers and are not to be construed as official or reflecting the view of the Navy Department or the Naval Service at large.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?